Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Next Previous
Trial Profile

Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Evolocumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FLOREY; PROFICIO
  • Sponsors Amgen

Most Recent Events

  • 16 Mar 2018 Results (n=63) assessing the effects of evolocumab against PCSK9 and lowers Lp (a) in subjects with baseline plasma apo (a) concentrations greater than 5nmol per L along with substudy results, published in the European Heart Journal.
  • 30 Aug 2017 Results assessing factorial effects of Evolocumab and Atorvastatin on lipoprotein metabolism, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
  • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top